5.77

5.68% 0.31

Mind Medicine Inc (MNMD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$5.46

Aprire:

$5.46

Volume 24 ore:

1.17M

Relative Volume:

0.63

Capitalizzazione di mercato:

$418.29M

Reddito:

$11.40B

Utile/perdita netta:

$-95.73M

Rapporto P/E:

-2.3551

EPS:

-2.45

Flusso di cassa netto:

$-64.37M

1 W Prestazione:

+12.26%

1M Prestazione:

-10.82%

6M Prestazione:

-10.12%

1 anno Prestazione:

-39.45%

Intervallo 1D:

$5.45

$5.8394

Intervallo di 1 settimana:

$5.0539

$5.85

Portata 52W:

$4.70

$10.44

Mind Medicine Inc Stock (MNMD) Company Profile

Nome

Mind Medicine Inc

Settore

Healthcare (1151)

Industria

Biotechnology (660)

Telefono

212-220-6633

Indirizzo

ONE WORLD TRADE CENTER, NEW YORK

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

MNMD's Discussions on Twitter

Confronta MNMD con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MNMD Mind Medicine Inc	5.77	418.29M	11.40B	-95.73M	-64.37M	-2.45
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-01-28	Iniziato	Evercore ISI	Outperform
2024-12-20	Iniziato	Chardan Capital Markets	Buy
2024-10-14	Ripresa	Leerink Partners	Outperform
2024-07-24	Iniziato	ROTH MKM	Buy
2024-05-29	Iniziato	Robert W. Baird	Outperform
2024-04-15	Iniziato	Leerink Partners	Outperform
2023-12-05	Iniziato	Canaccord Genuity	Buy
2022-12-09	Ripresa	ROTH Capital	Buy
2022-11-16	Iniziato	RBC Capital Mkts	Outperform
2022-08-26	Iniziato	Oppenheimer	Outperform
2022-08-10	Iniziato	Cantor Fitzgerald	Overweight
2022-05-04	Iniziato	ROTH Capital	Buy
2021-06-28	Iniziato	Maxim Group	Buy

Mostra tutto

Mind Medicine Inc Borsa (MNMD) Ultime notizie

Apr 16, 2025

Broadway Gold Mining : MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations - marketscreener.com

Apr 16, 2025

MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder - TipRanks

Apr 16, 2025

Oppenheimer maintains MindMed stock Outperform with $20 target By Investing.com - Investing.com India

Apr 16, 2025

Apr 15, 2025

MindMed launches phase 3 LSD study for depression By Investing.com - Investing.com Nigeria

Apr 15, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - GuruFocus

Apr 15, 2025

MindMed launches phase 3 LSD study for depression - Investing.com Australia

Apr 15, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of - GuruFocus

Apr 15, 2025

Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd) - marketscreener.com

Apr 15, 2025

Breakthrough: First-Ever Phase 3 LSD Depression Trial Begins at MindMed - Stock Titan

Apr 15, 2025

Apr 07, 2025

MindMed Appoints Schond L. Greenway as Chief Financial Officer - MarketScreener

Apr 07, 2025

Apr 04, 2025

MNMD stock touches 52-week low at $5.03 amid market challenges - Investing.com India

Apr 04, 2025

Long Term Trading Analysis for (MNMD) - news.stocktradersdaily.com

Apr 04, 2025

MNMD stock touches 52-week low at $5.03 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Mar 30, 2025

MNMD Stock Forecast From 2025 To 2040 - Exla Resources

Mar 30, 2025

Mar 26, 2025

Mind Medicine CEO Robert Barrow sells shares worth $142,941 By Investing.com - Investing.com Canada

Mar 26, 2025

MindMed Advances Clinical Programs with Strong Financial Backing - TipRanks

Mar 26, 2025

Mind Medicine CEO Robert Barrow sells shares worth $142,941 - Investing.com India

Mar 26, 2025

Mar 24, 2025

MindMed Announces New Employee Inducement Grants - Business Wire

Mar 24, 2025

MindMed Strengthens Brain Health Pipeline with Key Technical Talent Acquisition - Stock Titan

Mar 24, 2025

Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR

Mar 21, 2025

Mar 17, 2025

MindMed appoints new Chief Commercial Officer By Investing.com - Investing.com South Africa

Mar 17, 2025

MindMed Appoints Matt Wiley as Chief Commercial Officer - Quantisnow

Mar 17, 2025

MindMed appoints new Chief Commercial Officer - Investing.com

Mar 17, 2025

MindMed Taps Former Jazz Pharma Executive to Lead MM120 Anxiety Drug Launch - Stock Titan

Mar 17, 2025

Mar 12, 2025

MindMed’s SWOT analysis: psychedelic stock’s journey through mental health market - Investing.com

Mar 12, 2025

Mar 11, 2025

MindMed at Leerink’s Global Healthcare Conference: Strategic Insights on Psychedelics - Investing.com India

Mar 11, 2025

Mar 10, 2025

What is HC Wainwright’s Estimate for MNMD FY2029 Earnings? - Defense World

Mar 10, 2025

Robert W. Baird Cuts Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target to $16.00 - Defense World

Mar 10, 2025

Mind Medicine (MindMed)’s (MNMD) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 10, 2025

Mar 08, 2025

Mind Medicine’s (MNMD) Recent Achievements Boosting Stock - Markets Insider

Mar 08, 2025

Rhumbline Advisers Buys 4,868 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World

Mar 08, 2025

Oppenheimer & Co. Inc. Grows Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World

Mar 08, 2025

Mar 07, 2025

Sanctuary Advisors LLC Lowers Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World

Mar 07, 2025

H.C. Wainwright maintains MindMed stock Buy rating, $55 target - Investing.com India

Mar 07, 2025

Mind Medicine’s Promising Future: Buy Rating Backed by Strong Phase 3 Prospects and Financial Position - TipRanks

Mar 07, 2025